Chimeric antigen receptor-T (CAR-T) cell therapy is a precise immunotherapy for lymphoma.
First-pass extracted concept
Chimeric antigen receptor-T cell therapy for lymphoma
Candidate: concept label1 source documents4 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
CAR-T cell therapy for lymphoma
Evidence Snippets
Supporting Sources
Linked Claims
Diverse modifications to conventional CAR-T cells have been introduced to address efficacy and safety obstacles, including recognition-site addition, cytokine-domain coupling, immune-checkpoint blocking, and inclusion of suicide systems or safety switches.
Quoted textsource-backed
Diverse modifications have been introduced into conventional CAR-T cells to overcome these obstacles; examples include addition of recognition sites to prevent immune escape, coupling of cytokine domains to enhance killing ability, blocking of immune checkpoint signals to resist tumor microenvironments, and inclusion of suicide systems or safety switches to improve safety and flexibility.
The long-term efficacy of CAR-T cell therapy for lymphoma is challenged by tumor cell heterogeneity, immunosuppressive microenvironments, CAR-T cell exhaustion, and unmanageable adverse events.
Quoted textsource-backed
However, its long-term efficacy faces many challenges related to tumor cell heterogeneity, interference from immunosuppressive microenvironments, CAR-T cell exhaustion, and unmanageable adverse events.
Glycolysis, methylation, and acetylation have become crucial therapeutic targets for CAR-T cells.
Quoted textsource-backed
With increasing understanding of the importance of metabolism and epigenetics in cancer and cytotherapy, glycolysis, methylation, and acetylation have become crucial CAR-T cell therapeutic targets.
CAR-T cell therapy is a precise immunotherapy for lymphoma.
Quoted textsource-backed
Chimeric antigen receptor-T (CAR-T) cell therapy is a precise immunotherapy for lymphoma.